FIVE AND SIX MEMBERED HETERO S AND HETERO N FUSED RING COMPOUNDS

摘要

Novel heterocyclic compounds of Formula I FORM:1039117/C2/1 wherein R represents an aryl radical which may be substituted by alkyl, alkoxy, alkylthio, alkylsulphonal, alkyl- or dialkyl-amino, alkanoylamino, alkyl- or dialkyl-sulphamoyl groups, each alkyl radical having up to 4 carbon atoms, hydroxyl, amino, sulpho, sulphamoyl or trifluoromethyl groups or halogen atoms, and A and B independently represent an ethylene or trimethylene radical which may be substituted by alkyl and phenyl radicals, the o-phenylene or o-benzylene radical in which any benzene nucleus present can be substituted by alkyl or alkoxy radicals or by halogen atoms, and n represents 0 or 1, are prepared (1) by reacting a g or d ketocarboxylic acid of formula FORM:1039117/C2/2 where X represents a hydroxy, alkoxy or alkanoyloxy group, or a chlorine or bromine atom or its tautomeric form with a compound of formula H2N-B-SH, (2) by subjecting to conditions which split off water a compound of formula FORM:1039117/C2/3 or the tautomer thereof, and (3) by subjecting a reactive ester of a compound of Formula VII FORM:1039117/C2/4 to conditions which split off acid, and, in each case, the product may be oxidized to the corresponding sulphoxide. Therapeutic compositions which are useful as analgetic, anti - inflammatory, anaesthesia-potentiating and anti-convulsive agents and which may be administered orally, parenterally or rectally contain as active ingredient compounds of Formula I above. 2 - (Bromoalkyl) - 3 - mercapto - 3 - phenylphthalimidines may be prepared by treating 2 - (bromoalkyl) - 3 - hydroxy - 3 - phenylphthalimidine obtained from N-(bromoalkyl)-phthalimide and phenylmagnesium bromide, with hydrogen sulphide. The reactive esters of Formula VII used as starting materials in process (3) can be produced from the corresponding esters of the alcohol where -SH has been replaced by -OH, by treatment with hydrogen sulphide in the presence of an acid.